Similarly, using xenograft models in NOD/SCID mice reconstituted with human T lymphocytes, another group showed that a LAIR-2–Fc recombinant protein augmented tumor infiltration with CD8+ T cells, resulting in tumor control, and increased the antitumor effect of anti–PD-1 therapy (36). The gene discussed is CD8A; the disease is neoplasm.